Characteristics of rheumatoid arthritis patients initiating therapy with abatacept, other biologics, and non-biologic disease-modifying anti-rheumatic drugs

被引：0
|
作者：
Hoffman, Veena [1 ]
Simon, Teresa A. [2 ]
Liu, Nan [3 ]
Lin, Nancy D. [3 ]
机构：
[1] Optum, Ann Arbor, MI USA
[2] Bristol Myers Squibb, Pennington, NJ USA
[3] Optum, Boston, MA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2017年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
459
引用
收藏
页码：278 / 278
页数：1
相关论文
共 50 条
  • [1] Identification of Tuberculosis in Rheumatoid Arthritis Patients Initiating Therapy with Biologic or Non-Biologic Disease-Modifying Anti-Rheumatic Drugs Using Health Insurance Claims Data.
    Simon, T.
    Liu, N.
    Baker, N.
    Lin, N.
    Hoffman, V.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S41 - S41
  • [2] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    [J]. RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [3] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    [J]. Clinical Rheumatology, 2020, 39 : 787 - 794
  • [4] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [5] Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs
    Solomon, Daniel H.
    Kremer, Joel M.
    Fisher, Mark
    Curtis, Jeffrey R.
    Furer, Victoria
    Harrold, Leslie R.
    Hochberg, Marc C.
    Reed, George
    Tsao, Peter
    Greenberg, Jeffrey D.
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2014, 43 (04) : 489 - 497
  • [6] Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Mourouzis, Iordanis S.
    Manolis, Antonis S.
    Pantos, Constantinos
    [J]. CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (05) : 455 - 462
  • [7] Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated On Non-Biologic Disease-Modifying Anti-Rheumatic Drugs.
    Curtis, Jeffrey
    Gauthier, Genevieve
    Hiscock, Robert
    Zhang, Frank
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S782 - S783
  • [8] The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs
    Pombo-Suarez, Manuel
    Gomez-Reino, Juan
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 148
  • [9] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    [J]. CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [10] BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs
    Ledingham, Jo
    Gullick, Nicola
    Irving, Katherine
    Gorodkin, Rachel
    Aris, Melissa
    Burke, Jean
    Gordon, Patrick
    Christidis, Dimitrios
    Galloway, Sarah
    Hayes, Eranga
    Jeffries, Andrew
    Mercer, Scott
    Mooney, Janice
    van Leuven, Sander
    Galloway, James
    [J]. RHEUMATOLOGY, 2017, 56 (06) : 865 - 868
12345